{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T01:47:56Z","timestamp":1781920076821,"version":"3.54.5"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T00:00:00Z","timestamp":1690156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare, potentially life-threatening syndromes characterized by the development of necrotic epidermal and mucosal lesions. The most common etiologic cause of SJS\/TEN is drug-induced mechanisms. The group of drugs with high potential risk includes sulfonamides, anticonvulsants, non-steroidal anti-inflammatory drugs (NSAIDs), allopurinol, phenobarbital, etc. There is no gold standard treatment algorithm for SJS\/TEN. In medical practice, systemic glucocorticosteroids (sGCS), intravenous immunoglobulin (IVIG), plasmapheresis, and cyclosporine are used empirically and in various combinations. Recently published studies have demonstrated the efficacy of TNF-\u03b1 inhibitors as a promising approach in SJS\/TEN, including cases resistant to high-dose sGCS, with etanercept and infliximab being the most commonly used drugs. In a large multicenter study by Zhang J et al. (XXXX), 242 patients treated with etanercept, sGCS, or a combination of both had lower mortality compared to the control group. A shorter skin healing time was documented compared to sGCS monotherapy, thus reducing the risk of secondary infections. The published data show a high efficacy with THF-\u03b1 inhibitor blockade, but the safety of TNF-\u03b1 inhibitors in patients with SJS\/TEN is still questionable due to the paucity of available information. As all clinical research data should be accumulated to provide reliable evidence that the use of TNF-\u03b1 inhibitors may be beneficial in SJS\/TEN, we report a case of etoricoxib-associated SJS with progression to TEN in a 50-year-old woman who was refractory to high-dose sGCS therapy.<\/jats:p>","DOI":"10.3389\/fmed.2023.1210026","type":"journal-article","created":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T09:51:50Z","timestamp":1690192310000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Positive experience with TNF-\u03b1 inhibitor in toxic epidermal necrolysis resistant to high-dose systemic corticosteroids"],"prefix":"10.3389","volume":"10","author":[{"given":"Ekaterina A.","family":"Nikitina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daria S.","family":"Fomina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulyana A.","family":"Markina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergey S.","family":"Andreev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri V.","family":"Streltsov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana S.","family":"Kruglova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina S.","family":"Lebedkina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander V.","family":"Karaulov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryana A.","family":"Lysenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,7,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1016\/j.jaad.2020.02.066","article-title":"Society of dermatology hospitalists supportive care guidelines for the management of stevens-johnson syndrome\/toxic epidermal necrolysis in adults","volume":"82","author":"Seminario-Vidal","year":"2020","journal-title":"J Am Acad Dermatol."},{"key":"B2","volume-title":"Sindrom Stivensa\u2013Dzhonsona i sindrom Lajella u vzroslyh [Stevens-Johnson syndrome and Lyell's syndrome in adults]","author":"Lysenko","year":"2023"},{"key":"B3","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jaad.2007.08.039","article-title":"Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR study","volume":"58","author":"Schneck","year":"2008","journal-title":"J Am Acad Dermatol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1001\/jamadermatol.2016.5668","article-title":"Systemic immunomodulating therapies for stevens-johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis","volume":"153","author":"Zimmermann","year":"2017","journal-title":"JAMA Dermatol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"144","DOI":"10.2340\/00015555-0214","article-title":"Dexamethasone pulse therapy for stevens-johnson syndrome\/toxic epidermal necrolysis","volume":"87","author":"Kardaun","year":"2007","journal-title":"Acta Derm Venereol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1245e54","DOI":"10.1016\/j.burns.2014.02.006","article-title":"A systematic review of the management and outcome of toxic epidermal necrolysis treated in burns centres","volume":"40","author":"Mahar","year":"2014","journal-title":"Burns"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1182\/blood.V100.5.1721.h81702001721_1721_1727","article-title":"Cyclosporin A blocks the expression of lymphotoxin alpha, but not lymphotoxin beta, in human peripheral blood mononuclear cells","volume":"100","author":"Kuprash","year":"2002","journal-title":"Blood."},{"key":"B8","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/jid.2012.330","article-title":"TNF-\u03b1 and IFN-\u03b3 are potential inducers of Fas-mediated keratinocyte apoptosis through activation of inducible nitric oxide synthase in toxic epidermal necrolysis","volume":"133","author":"Viard-Leveugle","year":"2013","journal-title":"J Invest Dermatol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1097\/00006454-198205000-00005","article-title":"Stevens-Johnson syndrome in children","volume":"1","author":"Ginsburg","year":"1982","journal-title":"Pediatr Infect Dis J."},{"key":"B10","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1097\/00000658-198611000-00001","article-title":"Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids","volume":"204","author":"Halebian","year":"1986","journal-title":"Ann Surg."},{"key":"B11","first-page":"273","article-title":"Burn center care for patients with toxic epidermal necrolysis","volume":"180","author":"Kelemen","year":"1995","journal-title":"J Am Coll Surg."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1111\/bjd.12607","article-title":"The role of intravenous immunoglobulin in toxic epidermal necrolysis: a retrospective analysis of 64 patients managed in a specialized centre","volume":"169","author":"Lee","year":"2013","journal-title":"Br J Dermatol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1111\/j.1346-8138.2010.01154.x","article-title":"Efficacy of plasmapheresis for the treatment of severe toxic epidermal necrolysis: Is cytokine expression analysis useful in predicting its therapeutic efficacy?","volume":"38","author":"Narita","year":"2011","journal-title":"J Dermatol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1007\/s001340051063","article-title":"Lack of significant treatment effect of plasma exchange in the treatment of drug-induced toxic epidermal necrolysis?","volume":"25","author":"Furubacke","year":"1999","journal-title":"Intensive Care Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1111\/1346-8138.13430","article-title":"Severe cutaneous adverse drug reactions","volume":"43","author":"Chung","year":"2016","journal-title":"J Dermatol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1111\/j.1365-2133.2010.09863.x","article-title":"Open trial of cyclosporine treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"163","author":"Valeyrie-Allanore","year":"2010","journal-title":"Br J Dermatol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.jaad.2014.07.016","article-title":"Retrospective review of Stevens-Johnson syndrome\/toxic epidermal necrolysis treatment comparing intravenous immunoglobulin with cyclosporine","volume":"71","author":"Kirchhof","year":"2014","journal-title":"J Am Acad Dermatol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"13030\/qt3m82s074","DOI":"10.5070\/D32210032890","article-title":"Cyclosporine in toxic epidermal necrolysis: a brief review of the emerging therapeutic modality","volume":"22","author":"Kumar","year":"2016","journal-title":"Dermatol Online J."},{"key":"B19","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.jaad.2016.07.048","article-title":"Cyclosporine treatment for stevens-johnson syndrome\/toxic epidermal necrolysis: retrospective analysis of a cohort treated in a specialized referral center","volume":"76","author":"Lee","year":"2017","journal-title":"J Am Acad Dermatol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.jaad.2014.04.044","article-title":"Etanercept therapy for toxic epidermal necrolysis","volume":"71","author":"Paradisi","year":"2014","journal-title":"J Am Acad Dermatol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1684\/ejd.2020.3883","article-title":"A new case series on etanercept treatment for toxic epidermal necrolysis","volume":"30","author":"Paradisi","year":"2020","journal-title":"Eur J Dermatol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1172\/JCI93349","article-title":"Randomized, controlled trial of TNF-\u03b1 antagonist in CTL-mediated severe cutaneous adverse reactions","volume":"128","author":"Wang","year":"2018","journal-title":"J Clin Invest."},{"key":"B23","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1111\/j.1346-8138.2009.00616.x","article-title":"Toxic epidermal necrolysis successfully treated with etanercept","volume":"36","author":"Gubinelli","year":"2009","journal-title":"J Dermatol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1111\/1346-8138.15058","article-title":"Successful treatment of interstitial lung disease related to Stevens-Johnson syndrome\/toxic epidermal necrolysis overlap with etanercept: a case report and published work review","volume":"46","author":"Wang","year":"2019","journal-title":"J Dermatol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"adv00723","DOI":"10.2340\/actadv.v102.2243","article-title":"Toxic epidermal necrolysis caused by apalutamide: a case report of treatment using etanercept with conventional steroid therapy","volume":"102","author":"Osawa","year":"2022","journal-title":"Acta Derm Venereol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1016\/j.jaad.2022.01.039","article-title":"Inhibition of tumor necrosis factor improves conventional steroid therapy for Stevens-Johnson syndrome\/toxic epidermal necrolysis in a cohort of patients","volume":"86","author":"Ao","year":"2022","journal-title":"J Am Acad Dermatol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/j.jaip.2022.01.038","article-title":"Evaluation of combination therapy with etanercept and systemic corticosteroids for stevens-johnson syndrome and toxic epidermal necrolysis: a multicenter observational study","volume":"10","author":"Zhang","year":"2022","journal-title":"J Allergy Clin Immunol Pract."},{"key":"B28","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1046\/j.1523-1747.2000.00061.x","article-title":"SCORTEN: a severity-of-illness score for toxic epidermal necrolysis","volume":"115","author":"Fouchard","year":"2000","journal-title":"J investigate Dermatol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/clpt.2009.252","article-title":"ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson Syndrome and toxic epidermal necrolysis: comparison with case-control analysis","volume":"80","author":"Sassolas","year":"2010","journal-title":"Clinical Pharmacol Therapeutic."},{"key":"B30","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s12016-017-8654-z","article-title":"Current perspectives on stevens-johnson syndrome and toxic epidermal necrolysis","volume":"54","author":"Lerch","year":"2018","journal-title":"Clinic Rev Allergy Immunol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2234","DOI":"10.1038\/sj.jid.5701033","article-title":"The risk of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with nonsteroidal antiinflammatory drugs: a multinational perspective","volume":"30","author":"Mockenhaupt","year":"2003","journal-title":"J Rheumatol."},{"key":"B32","unstructured":"2022"},{"key":"B33","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1111\/j.1346-8138.2010.00893.x","article-title":"Etoricoxib-induced toxic epidermal necrolysis: successful treatment with infliximab","volume":"37","author":"Kreft","year":"2010","journal-title":"J Dermatol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"221","DOI":"10.4103\/0253-7613.153436","article-title":"A case report on toxic epidermal necrolysis with etoricoxib","volume":"47","author":"Kameshwari","year":"2015","journal-title":"Indian J Pharmacol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"FD01","DOI":"10.7860\/JCDR\/2015\/14221.6244","article-title":"Stevens johnson syndrome-toxic epidermal necrolysis overlap secondary to interaction between methotrexate and etoricoxib: a case report","volume":"9","author":"Rachana","year":"2015","journal-title":"J Clin Diagn Res."},{"key":"B36","doi-asserted-by":"publisher","first-page":"139","DOI":"10.4103\/ijp.IJP_39_17","article-title":"Etoricoxib-induced toxic epidermal necrolysis: a fatal case report","volume":"50","author":"Roy","year":"2018","journal-title":"Indian J Pharmacol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/428486a","article-title":"Medical genetics: a marker for Stevens-Johnson syndrome","volume":"428","author":"Chung","year":"2004","journal-title":"Nature."},{"key":"B38","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1056\/NEJMoa1213096","article-title":"HLA-B*13:01 and the dapsone hypersensitivity syndrome","volume":"369","author":"Zhang","year":"2013","journal-title":"n Engl J Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jdermsci.2008.06.003","article-title":"Toxic epidermal necrolysis and Stevens-Johnson syndrome: soluble Fas ligand involvement in the pathomechanisms of these diseases","volume":"52","author":"Abe","year":"2008","journal-title":"J Dermatol Sci."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1038\/nm.1884","article-title":"Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"14","author":"Chung","year":"2008","journal-title":"Nat Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"5243","DOI":"10.4049\/jimmunol.174.9.5243","article-title":"Granulysin, a cytolytic molecule, is also a chemoattractant and proinflammatory activator","volume":"174","author":"Deng","year":"2005","journal-title":"J Immunol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.jaci.2013.04.036","article-title":"A new nucleic acid-based agent inhibits cytotoxic T lymphocyte-mediated immune disorders","volume":"132","author":"Wang","year":"2013","journal-title":"J Allergy Clin Immunol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1001\/archderm.130.5.605","article-title":"Macrophages and tumor necrosis factor alpha in toxic epidermal necrolysis","volume":"130","author":"Paquet","year":"1994","journal-title":"Arch Dermatol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1111\/j.0022-202X.2004.23439.x","article-title":"Evaluation of the potential role of cytokines in toxic epidermal necrolysis","volume":"123","author":"Nassif","year":"2004","journal-title":"J Invest Dermatol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1210026\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T09:52:20Z","timestamp":1690192340000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1210026\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,24]]},"references-count":44,"alternative-id":["10.3389\/fmed.2023.1210026"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2023.1210026","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,24]]},"article-number":"1210026"}}